Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice
- 196 Downloads
Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology in many somatic tissues, but has only limited efficacy in the brain tissue of the animals. In the current work, ERT of AGU mice was initiated at the age of 1 week with three different dosage schedules of recombinant glycosylasparaginase. The animals received either 3.4 U of AGA/kg every second day for 2 weeks (Group 1), 1.7 U/kg every second day for 9 days followed by an enzyme injection once a week for 4 weeks (Group 2) or 17 U/kg at the age of 7 and 9 days (Group 3). In the Group 1 and Group 3 mice, ERT reduced the amount of aspartylglucosamine by 34 and 41% in the brain tissue, respectively. No therapeutic effect was observed in the brain tissue of Group 2 mice. As in the case of adult AGU mice, the AGA therapy was much more effective in the somatic tissues than in the brain tissue of the newborn AGU mice. The combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease.
KeywordsEnzyme Replacement Therapy Fabry Disease Somatic Tissue Lysosomal Storage Disease Enzyme Dose
Central nervous system
Enzyme replacement therapy
This work was financially supported by grants from The Sigrid Juselius Foundation (I.M.), the Pediatric Research Foundation (Ulla Hjelt Fund) (I.M.), and Kuopio University Hospital (EVO grant #5100).
- Arvio M, Autio S, Mononen T (1997) Clinical manifestations of aspartylglycosaminuria. In: Mononen I, Aronson NN (eds) Lysosomal storage disease: aspartylglycosaminuria. R.G.Landes/Springer, Austin, pp 19–28Google Scholar
- Aula P, Jalanko A, Peltonen L (2001) Aspartylglucosaminuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease I–VII. McGraw-Hill, New York, pp 3535–3550Google Scholar
- Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469–475CrossRefPubMedGoogle Scholar
- Mononen I, Aronson NN Jr (1997) Lysosomal storage disease: aspartylglycosaminuria. R.G.Landes/Springer, AustinGoogle Scholar
- Vogler C, Sands MS, Levy B, Galvin N, Birkenmeier EH, Sly WS (1996) Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res 39:1050–1054CrossRefPubMedGoogle Scholar